On August 3, 2026, Genprex announced a collaboration with Roche Diagnostics to validate TROP2 as a biomarker for patient selection in non-small cell lung cancer clinical trials. The partnership leverages Roche's FDA Breakthrough Device Designation for an AI-driven companion diagnostic using the same TROP2 antibody employed by Genprex. Preclinical and clinical data suggest that high TROP2 and low PTEN expression levels correlate with improved progression-free survival. Genprex expects to complete validation studies by late 2026, aiming to accelerate patient recruitment and refine precision medicine strategies for NSCLC. Genprex is a biopharmaceutical company focused on developing targeted therapies for cancer and diabetes.
